Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland.

Carcinoma, Mucoepidermoid / pathology Humans Carcinoma, Adenoid Cystic / pathology Salivary Gland Neoplasms / pathology Biomarkers, Tumor / analysis
Adenoid cystic carcinoma Genetics Mucoepidermoid carcinoma Salivary gland neoplasms Tumor biomarkers microRNAs

Journal

Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 08 01 2024
accepted: 12 02 2024
medline: 25 4 2024
pubmed: 25 4 2024
entrez: 24 4 2024
Statut: epublish

Résumé

Salivary gland tumors (SGTs) are rare and highly heterogeneous lesions, making diagnosis a challenging activity. In addition, the small number of studies and samples evaluated difficults the determination of prognosis and diagnosis. Despite the solid advances achieved by research, there is still an intense need to investigate biomarkers for diagnosis, prognosis and that explain the evolution and progression of SGTs. We performed a comprehensive literature review of the molecular alterations focusing on the most frequent malignant SGTs: mucoepidermoid carcinoma and adenoid cystic carcinoma. Due to the importance of biomarkers in the tumorigenenic process, this review aimed to address the mechanisms involved and to describe molecular and biomarker pathways to better understand some aspects of the pathophysiology of salivary gland tumorigenesis. Molecular analysis is essential not only to improve the diagnosis and prognosis of the tumors but also to identify novel driver pathways in the precision medicine scenario.

Sections du résumé

BACKGROUND BACKGROUND
Salivary gland tumors (SGTs) are rare and highly heterogeneous lesions, making diagnosis a challenging activity. In addition, the small number of studies and samples evaluated difficults the determination of prognosis and diagnosis. Despite the solid advances achieved by research, there is still an intense need to investigate biomarkers for diagnosis, prognosis and that explain the evolution and progression of SGTs.
METHODS METHODS
We performed a comprehensive literature review of the molecular alterations focusing on the most frequent malignant SGTs: mucoepidermoid carcinoma and adenoid cystic carcinoma.
RESULTS RESULTS
Due to the importance of biomarkers in the tumorigenenic process, this review aimed to address the mechanisms involved and to describe molecular and biomarker pathways to better understand some aspects of the pathophysiology of salivary gland tumorigenesis.
CONCLUSIONS CONCLUSIONS
Molecular analysis is essential not only to improve the diagnosis and prognosis of the tumors but also to identify novel driver pathways in the precision medicine scenario.

Identifiants

DOI: 10.1007/s12105-024-01629-2 PMID: 38658430
pubmed: 38658430
doi: 10.1007/s12105-024-01629-2
pii: 10.1007/s12105-024-01629-2
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES)
ID : Finance Code 001
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES)
ID : Finance Code 001
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES)
ID : Finance Code 001
Organisme : São Paulo Research Foundation (FAPESP)
ID : 14/50943-1
Organisme : Brazilian National Research Council (CNPq)
ID : 465682/2014-6

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Porccheri C, Meisel CT, Mitsiadis TA (2020) Molecular and Cellular Modelling of Salivary Gland Tumors Open New landscapes in diagnosis and treatment. Cancer 12:3107. https://doi.org/10.3390/cancers12113107
doi: 10.3390/cancers12113107
Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J (2018) Salivary secretion in health and disease. J Oral Rehabil 45:730–746. https://doi.org/10.1111/joor.12664
doi: 10.1111/joor.12664 pubmed: 29878444
Ghannam MG, Singh P (2022) Anatomy, Head and Neck, salivary glands. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)
El-Naggar AK, Chan JKC, Grandis JR et al (2017) WHO classification of head and neck tumours. In: World Health Organization classification of tumours. 4th edition. Lyon (France): International Agency for Research on Cancer (IARC), pp 163–84
Gatta G, Guzzo M, Locati LD, McGurk M, Prott FJ (2020) Major and minor salivary gland tumours. Crit Rev Oncol Hematol 152:102959. https://doi.org/10.1016/j.critrevonc.2020.102959
doi: 10.1016/j.critrevonc.2020.102959 pubmed: 32485526
Westergaard-Nielsen M, Godballe C, Eriksen JG et al (2021) Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome. Eur Arch Otorhinolaryngol 278:1179–1188. https://doi.org/10.1007/s00405-020-06205-2
doi: 10.1007/s00405-020-06205-2 pubmed: 32691231
Pang J, Houlton JJ (2022) Management of malignant salivary gland conditions. SurgClin North Am 102:325–333. https://doi.org/10.1016/j.suc.2021.12.008
doi: 10.1016/j.suc.2021.12.008
Lima SS, Soares AF, de Amorim RF (2005) Epidemiologic profile of salivary gland neoplasms: analysis of 245 cases. Braz J Otorhinolaryngol 71. https://doi.org/10.1016/s1808-8694(15)31332-x . :335 – 40
Kordzińska-Cisek I, Cisek P, Grzybowska-Szatkowska L (2020) The role of prognostic factors in salivary gland tumors treated by surgery and adjuvant radio- or chemoradiotherapy - A single Institution experience. CancerManag Res 12:1047–1067. https://doi.org/10.2147/CMAR.S233431
doi: 10.2147/CMAR.S233431
de Oliveira FA, Duarte EC, Taveira CT et al (2009) Salivary gland tumor: a review of 599 cases in a Brazilian population. Head Neck Pathol 3:271–275. https://doi.org/10.1007/s12105-009-0139-9
doi: 10.1007/s12105-009-0139-9 pubmed: 20596844 pmcid: 2811571
Young A, Okuyemi OT (2022) Malignant salivary gland tumors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)
Dos Santos ES, Rodrigues-Fernandes CI, Speight PM et al (2021) Impact of tumor site on the prognosis of salivary gland neoplasms: a systematic review and meta-analysis. Crit Rev Oncol/Hematol 162:103352. https://doi.org/10.1016/j.critrevonc.2021.103352
doi: 10.1016/j.critrevonc.2021.103352 pubmed: 33991662
Nagano CP, Coutinho-Camillo CM, Pinto CA et al (2016) Cytokeratin immunoprofile of primary and metastatic adenoid cystic carcinoma of salivary glands: a report of two cases. Autops Case Rep 6:57–63. https://doi.org/10.4322/acr.2016.056
doi: 10.4322/acr.2016.056 pubmed: 28210575 pmcid: 5304563
Coca-Pelaz A, Rodrigo JP, Triantafyllou A et al (2015) Salivary mucoepidermoid carcinoma revisited. Eur Arch Otorhinolaryngol 272:799–819. https://doi.org/10.1097/01.pap.0000213058.74509.d3
doi: 10.1097/01.pap.0000213058.74509.d3 pubmed: 24771140
Chen MM, Roman SA, Sosa JA et al (2014) Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients. Head Neck 36:158–163. https://doi.org/10.1002/hed.23256
doi: 10.1002/hed.23256 pubmed: 23765800
Skalova A, Leivo I, Hellquist H et al (2021) High-grade Transformation/Dedifferentiation in Salivary Gland carcinomas: occurrence across subtypes and clinical significance. Adv Anat Pathol 28:107–118. https://doi.org/10.1097/PAP.0000000000000298
doi: 10.1097/PAP.0000000000000298 pubmed: 33825717
Hellquist H, Skálová A, Barnes L et al (2016) Cervical lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: a collective International Review. Adv Ther 33:357–368. https://doi.org/10.1007/s12325-016-0298-5
doi: 10.1007/s12325-016-0298-5 pubmed: 26895332 pmcid: 4833802
Dillon PM, Petroni GR, Horton BJ et al (2017) A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res 23:4138–4145. https://doi.org/10.1158/1078-0432.CCR-16-2942
doi: 10.1158/1078-0432.CCR-16-2942 pubmed: 28377480 pmcid: 5540767
Van Herpen C, Vander Poorten V, Skalova A et al (2022) Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment, and follow-up. ESMO Open 7:100602. https://doi.org/10.1016/j.esmoop.2022.100602
doi: 10.1016/j.esmoop.2022.100602 pubmed: 36567082 pmcid: 9808465
Alfieri S, Granata R, Bergamini C et al (2017) Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol 66:58–63. https://doi.org/10.1016/j.oraloncology.2016.12.016
doi: 10.1016/j.oraloncology.2016.12.016 pubmed: 28249649
Cavalieri S, Mariani L, Vander Poorten V et al (2020) Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer 136:35–42. https://doi.org/10.1016/j.ejca.2020.05.013
doi: 10.1016/j.ejca.2020.05.013 pubmed: 32629365
Namboodiripad A (2014) A review: immunological markers for malignant salivary gland tumours. J Oral BiolCraniofac Res. https://doi.org/10.1016/j.jobcr.2014.05.003 . 4:127 – 34
doi: 10.1016/j.jobcr.2014.05.003
Meyer MT, Watermann C, Dreyer T et al (2021) 2021 update on diagnostic markers and translocation in salivary gland tumors. Int J MolSci 22:6771. https://doi.org/10.3390/ijms22136771
doi: 10.3390/ijms22136771
Byrd SA, Spector ME, Carey TE et al (2013) Predictors of recurrence and survival for head and neck mucoepidermoid carcinoma. Otolaryngol Head Neck Surg 149:402–408. https://doi.org/10.1177/0194599813489659
doi: 10.1177/0194599813489659 pubmed: 23695589 pmcid: 4106041
Peraza A, Gómez R, Beltran J et al (2020) Mucoepidermoid carcinoma. An update and review of the literature. J Stomatol Oral Maxillofac Surg 121:713–720. https://doi.org/10.1016/j.jormas.2020.06.003
doi: 10.1016/j.jormas.2020.06.003 pubmed: 32565266
Cantù G (2021) Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from a etiopathogenesis to diagnosis. ActaOtorhinolaryngolItal 41:206–214. https://doi.org/10.14639/0392-100X-N1379
doi: 10.14639/0392-100X-N1379
He D, Zhu S, Zhao Q, Chang H, Li G, Shao Q, Zhang C, Wu P (2023) Epidemiology of and factors associated with overall survival for patients with head and neck adenoid cystic carcinoma. J Cancer Res Clin Oncol 149(15):14071–14080. https://doi.org/10.1007/s00432-023-05224-w
doi: 10.1007/s00432-023-05224-w pubmed: 37548774
Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med (Maywood) 243:213–221. https://doi.org/10.1177/1535370217750088
Toper MH, Sarioglu S (2021) Molecular Pathology of Salivary Gland neoplasms: Diagnostic, Prognostic, and predictive perspective. Adv Anat Pathol 28:81–93. https://doi.org/10.1097/PAP.0000000000000291
doi: 10.1097/PAP.0000000000000291 pubmed: 33405400
Li A, Yang DH (2020) Application of immunohistochemistry in Basic and Clinical studies. Methods MolBiol 2108:43–55. https://doi.org/10.1007/978-1-0716-0247-8_4
doi: 10.1007/978-1-0716-0247-8_4
Cleymaet R, Vermassen T, Coopman R et al (2022) The Therapeutic Landscape of Salivary Gland malignancies-where are we now? Int J MolSci 23:14891. https://doi.org/10.3390/ijms232314891
doi: 10.3390/ijms232314891
Adelstein DJ, Koyfman SA, El-Naggar AK et al (2012) Biology and management of salivary gland cancers. https://doi.org/10.1016/j.semradonc.2012.03.009 . SeminRadiatOncol 22:245 – 53
Ramos-Vara JA (2005) Technical aspects of immunohistochemistry. Vet Pathol 42:405–426. https://doi.org/10.1354/vp.42-4-405
doi: 10.1354/vp.42-4-405 pubmed: 16006601
Sukswai N, Khoury JD (2019) Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection. CurrHematolMalig Rep 14. https://doi.org/10.1007/s11899-019-00533-9 . :368 – 75
Gao XL, Wu JS, Cao MX et al (2017) Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS ONE 12:e0171341. https://doi.org/10.1371/journal.pone.0171341
doi: 10.1371/journal.pone.0171341 pubmed: 28152077 pmcid: 5289574
Teixeira LN, Janner ÉC, Teixeira T et al (2019) Comparison of p63/p40 expression with myoepithelial markers in minor salivary gland tumors. Int J SurgPathol 27:360–371. https://doi.org/10.1177/1066896918813678
doi: 10.1177/1066896918813678
Larsen SR, Bjørndal K, Godballe C, Krogdahl A (2012) Prognostic significance of Ki-67 in salivary gland carcinomas. J Oral Pathol Med 41:598–602. https://doi.org/10.1111/j.1600-0714.2012.01148.x
doi: 10.1111/j.1600-0714.2012.01148.x pubmed: 22530699
Bagulkar BB, Gawande M, Chaudhary M et al (2015) XIAP and Ki-67: a correlation BetweenAntiapoptotic and proliferative marker expression in Benign and Malignant tumours of salivary gland: an immunohistochemical study. J ClinDiagn Res 9:EC01–4. https://doi.org/10.7860/JCDR/2015/11690.5604
doi: 10.7860/JCDR/2015/11690.5604
Warner KA, Adams A, Bernardi L et al (2013) Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol 49:1059–1066. https://doi.org/10.1016/j.oraloncology.2013.08.004
doi: 10.1016/j.oraloncology.2013.08.004 pubmed: 24035723
Belulescu IC, Mărgăritescu C, Dumitrescu CI et al (2020) Immunophenotypical alterations with impact on the epithelial-mesenchymal transition (EMT) process in salivary gland adenoid cystic carcinomas. Rom J MorpholEmbryol 61:175–187. https://doi.org/10.47162/RJME.61.1.20
doi: 10.47162/RJME.61.1.20
Moore A, Bar Y, Maurice-Dror C et al (2020) Next-generation sequencing in salivary gland carcinoma: targetable alterations lead to a therapeutic advantage-multicenter experience. Head Neck 42:599–607. https://doi.org/10.1002/hed.26026
doi: 10.1002/hed.26026 pubmed: 31762146
Rito M, Fonseca I (2018) Salivary gland neoplasms: does morphological diversity reflect Tumor Heterogeneity. Pathobiol 85:85–95. https://doi.org/10.1159/000479070
doi: 10.1159/000479070
Ferrarotto R, Mitani Y, McGrail DJ et al (2021) Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 27:852–864. https://doi.org/10.1158/1078-0432.CCR-20-1192
doi: 10.1158/1078-0432.CCR-20-1192 pubmed: 33172898
Even C, Lassen U, Merchan J et al (2020) Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs 38:402–409. https://doi.org/10.1007/s10637-019-00739-x
doi: 10.1007/s10637-019-00739-x pubmed: 30953269
Majewska H, Gorczyński A, Czapiewski P et al (2021) ALK alterations in salivary gland carcinomas. Virchows Arch. https://doi.org/10.1007/s00428-020-02971-w . 478:933 – 41
doi: 10.1007/s00428-020-02971-w pubmed: 33237469
Dos Santos ES, Ramos JC, Normando AGC et al (2020) Epigenetic alterations in salivary gland tumors. Oral Dis 26:1610–1618. https://doi.org/10.1111/odi.13253
doi: 10.1111/odi.13253 pubmed: 31829479
Li Y, Gu F, He Y et al (2023) MicroRNA in adenoid cystic carcinoma (review). Int J Oncol 62:17. https://doi.org/10.3892/ijo.2022.5465
doi: 10.3892/ijo.2022.5465 pubmed: 36484384
Salehinejad J, Mohtasham N, Bagherpour A et al (2014) Evaluation of c-kit protein (CD117) expression in common salivary gland neoplasms. J Oral Maxillofac Pathol 18:177–182. https://doi.org/10.4103/0973-029X.140732
doi: 10.4103/0973-029X.140732
Nishida H, Daa T, Kashima K et al (2015) KIT (CD117) expression in Benign and malignant sweat gland tumors. Am J Dermatopathol 37:898–805. https://doi.org/10.1097/DAD.0000000000000301
doi: 10.1097/DAD.0000000000000301 pubmed: 25634571 pmcid: 4894802
Tariq H, Anjum S, Din HU et al (2017) Diagnostic utility of C-kit protein (CD117) expression in differentiating adenoid cystic carcinoma and polymorphous low-grade Adenocarcinoma. Pak J Med Sci 33:1376–1380. https://doi.org/10.12669/pjms.336.13373
doi: 10.12669/pjms.336.13373 pubmed: 29492062 pmcid: 5768828
Tang YL, Fan YL, Jiang J et al (2014) C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget 5:1491–1501. https://doi.org/10.18632/oncotarget.1606
doi: 10.18632/oncotarget.1606 pubmed: 24721839 pmcid: 4039226
Phuchareon J, van Zante A, Overdevest JB et al (2014) c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol 7: 537 – 45. https://doi.org/10.1016/j.tranon.2014.07.006
Hou H, Jia D, Yan W et al (2020) KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors. Transl Cancer Res 9:4703–4714. https://doi.org/10.21037/tcr-20-637
doi: 10.21037/tcr-20-637 pubmed: 35117834 pmcid: 8797755
Freiberger SN, Brada M, Fritz C et al (2021) SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 23:473–487. https://doi.org/10.1016/j.neo.2021.03.008
Fukai J, Fujita K, Yamoto T et al (2014) Intracranial extension of adenoid cystic carcinoma: potential involvement of EphA2 expression and epithelial-mesenchymal transition in tumor metastasis: a case report. BMC Res Notes 7:131. https://doi.org/10.1186/1756-0500-7-131
doi: 10.1186/1756-0500-7-131 pubmed: 24606764 pmcid: 3975335
Lorini L, Ardighieri L, Bozzola A et al (2021) Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol 115:105213. https://doi.org/10.1016/j.oraloncology.2021.105213
doi: 10.1016/j.oraloncology.2021.105213 pubmed: 33578204
Ho AS, Ochoa A, Jayakumaran G et al (2019) Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest 129:4276–4289. https://doi.org/10.1172/JCI128227
doi: 10.1172/JCI128227 pubmed: 31483290 pmcid: 6763222
Persson M, Andersson MK, Mitani Y, Brandwein-Weber MS, Frierson HF Jr, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G (2022) Rearrangements, expression, and clinical significance of MYB and MYBL1 in adenoid cystic carcinoma: a multi-institutional study. Cancers (Basel) 14:3691. https://doi.org/10.3390/cancers14153691
doi: 10.3390/cancers14153691 pubmed: 35954356
Ferrarotto R, Mitani Y, Diao L et al (2017) Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic Carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 35:352–360. https://doi.org/10.1200/JCO.2016.67.5264
doi: 10.1200/JCO.2016.67.5264
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P (2018) A phase 1 dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 29:1561–1568. https://doi.org/10.1093/annonc/mdy171
doi: 10.1093/annonc/mdy171 pubmed: 29726923
Karpinets TV, Mitani Y, Liu B et al (2021) Whole-genome sequencing of Common Salivary Gland carcinomas: Subtype-Restricted and Shared genetic alterations. Clin Cancer Res 27:3960–3969. https://doi.org/10.1158/1078-0432.CCR-20-4071
doi: 10.1158/1078-0432.CCR-20-4071 pubmed: 34011559 pmcid: 8598082
Humtsoe JO, Kim HS, Jones L, Cevallos J, Boileau P, Kuo F, Morris LGT, Ha P (2022) Development and characterization of MYB-NFIB Fusion expression in Adenoid cystic carcinoma. Cancers (Basel) 14:2263. https://doi.org/10.3390/cancers14092263
doi: 10.3390/cancers14092263 pubmed: 35565392
Yan K, Yesensky J, Hasina R et al (2018) Genomics of mucoepidermoid and adenoid cystic carcinomas. Laryngoscope Investig Otolaryngol 3:56–61. https://doi.org/10.1002/lio2.139
doi: 10.1002/lio2.139
Fujii K, Murase T, Beppu S et al (2017) MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. Histopathology 71:823–834. https://doi.org/10.1111/his.13281
doi: 10.1111/his.13281 pubmed: 28594149
Shibata E, Morita KI, Kayamori K et al (2021) Detection of novel fusion genes by next-generation sequencing-based targeted RNA sequencing analysis in adenoid cystic carcinoma of head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol 132:426–433. https://doi.org/10.1016/j.oooo.2021.03.020
doi: 10.1016/j.oooo.2021.03.020 pubmed: 34413003
Yu GT, Bu LL, Zhao YY et al (2014) Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 4:764–775
pubmed: 25520866 pmcid: 4266710
Chae YK, Chung SY, Davis AA et al (2015) Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget 6:37117–37134. https://doi.org/10.18632/oncotarget.5076
doi: 10.18632/oncotarget.5076 pubmed: 26359351 pmcid: 4741919
Jiang LC, Huang SY, Zhang DS et al (2014) Expression of beclin 1 in primary salivary adenoid cystic carcinoma and its relation to Bcl-2 and p53 and prognosis. Braz J Med Biol Res 47:252–258. https://doi.org/10.1590/1414-431X20133231
doi: 10.1590/1414-431X20133231 pubmed: 24554038 pmcid: 3982947
Nör F, Warner KA, Zhang Z et al (2018) Therapeutic inhibition of the MDM2-p53 Interaction prevents recurrence of adenoid cystic carcinomas. CQn Cancer Res 23:1036–1048. https://doi.org/10.1158/1078-0432.CCR-16-1235
doi: 10.1158/1078-0432.CCR-16-1235
Li Q, Huang P, Zheng C et al (2017) Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis. Oncotarget 8:29458–29473. https://doi.org/10.18632/oncotarget.15297
doi: 10.18632/oncotarget.15297 pubmed: 28206977 pmcid: 5438744
Humtsoe JO, Kim HS, Leonard B et al (2021) Newly identified members of FGFR1 splice variants engage in cross-talk with AXL/AKT Axis in Salivary Adenoid cystic carcinoma. Cancer Res 81:1001–1013. https://doi.org/10.1158/0008-5472.CAN-20-1780
doi: 10.1158/0008-5472.CAN-20-1780 pubmed: 33408119
Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726. https://doi.org/10.1038/bjc.2011.605
doi: 10.1038/bjc.2011.605 pubmed: 22240798 pmcid: 3282188
Cao Y, Liu H, Xia SL et al (2019) PTEN downregulates WD repeat containing protein 66 in salivary adenoid cystic carcinoma. Oncol Rep 41:1827–1836. https://doi.org/10.3892/or.2018.6931
doi: 10.3892/or.2018.6931 pubmed: 30569117
Guazzo E, Cooper C, Wilkinson L et al (2021) Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck 43:768–777. https://doi.org/10.1002/hed.26529
doi: 10.1002/hed.26529 pubmed: 33169486
Wang WM, Zhao ZL, Zhang WF et al (2015) Role of hypoxia-inducible factor-1α and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. Mol Med Rep 12:3432–3438. https://doi.org/10.3892/mmr.2015.3815
doi: 10.3892/mmr.2015.3815 pubmed: 25997612 pmcid: 4526044
Wang Y, Hu J, Wang Y et al (2018) EGFR activation induced snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. Cell Cycle 17:1457–1470. https://doi.org/10.1080/15384101.2018.1489177
doi: 10.1080/15384101.2018.1489177 pubmed: 29954240 pmcid: 6132955
Xia R, Zhou R, Tian Z et al (2013) High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med 137:1761–1769. https://doi.org/10.5858/arpa.2012-0704-OA
doi: 10.5858/arpa.2012-0704-OA pubmed: 24283856
Daa T, Kashima K, Kondo Y et al (2008) Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland. APMIS 116:21–26. https://doi.org/10.1111/j.1600-0463.2008.00773.x
doi: 10.1111/j.1600-0463.2008.00773.x pubmed: 18254776
Ling S, Rettig EM, Tan M et al (2016) Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. Int J Oncol 49:225–234. https://doi.org/10.3892/ijo.2016.3532
doi: 10.3892/ijo.2016.3532 pubmed: 27212063 pmcid: 4902070
Brown AL, Al-Samadi A, Sperandio M et al (2019) MiR-455-3p, miR-150 and miR-375 are aberrantly expressed in salivary gland adenoid cystic carcinoma and polymorphous adenocarcinoma. J Oral Pathol Med 48:840–845. https://doi.org/10.1111/jop.12894
doi: 10.1111/jop.12894 pubmed: 31165496
Andreasen S, Tan Q, Agander TK et al (2018) MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. Virchows Arch 473:329–340. https://doi.org/10.1007/s00428-018-2423-0
doi: 10.1007/s00428-018-2423-0 pubmed: 30069755
Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM, El-Naggar AK (2013) MicroRNA profiling of salivary adenoid cystic carcinoma: association of mir-17-92 upregulation with poor outcome. PLoS ONE 8:e66778. https://doi.org/10.1371/journal.pone.0066778
doi: 10.1371/journal.pone.0066778 pubmed: 23825564 pmcid: 3692530
Kerche LE, de Sousa EA, Squarize CH et al (2022) EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters. Mol Biol Rep 49:2157–2167. https://doi.org/10.1007/s11033-021-07033-1
doi: 10.1007/s11033-021-07033-1
Liu L, Hu Y, Fu J, Yang X, Zhang Z (2013) MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma. J Oral Pathol Med 42(2):140–147. https://doi.org/10.1111/j.1600-0714.2012.01189.x
doi: 10.1111/j.1600-0714.2012.01189.x pubmed: 22823535
Kumar P, Kumawat RK, Uttam V et al (2023) The imminent role of microRNAs in salivary adenoid cystic carcinoma. Transl Oncol 27:101573. https://doi.org/10.1016/j.tranon.2022.101573
doi: 10.1016/j.tranon.2022.101573
Xu B, Jungbluth AA, Frosina D et al (2019) The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology 75:672–682. https://doi.org/10.1111/his.13944
doi: 10.1111/his.13944 pubmed: 31237963 pmcid: 6812589
Harada K, Ferdous T, Ueyama Y (2018) PD-L1 expression in malignant salivary gland tumors. BMC Cancer 18:156. https://doi.org/10.1186/s12885-018-4069-3
doi: 10.1186/s12885-018-4069-3 pubmed: 29409471 pmcid: 5801834
Mukaigawa T, Hayashi R, Hashimoto K et al (2016) Programmed death ligand-1 expression is associated with poor disease-free survival in salivary gland carcinomas. J Surg Oncol 114:36–43. https://doi.org/10.1002/jso.24266
doi: 10.1002/jso.24266
Mosconi C, de Arruda JAA, de Farias ACR et al (2019) Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol 88:95–101. https://doi.org/10.1016/j.oraloncology.2018.11.028
doi: 10.1016/j.oraloncology.2018.11.028 pubmed: 30616805
Nakano T, Takizawa K, Uezato A et al (2019) Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol 90:30–37. https://doi.org/10.1016/j.oraloncology.2019.01.015
doi: 10.1016/j.oraloncology.2019.01.015 pubmed: 30846173
Morita M, Murase T, Okumura Y et al (2020) Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology 76:1013–1022. https://doi.org/10.1111/his.14100
doi: 10.1111/his.14100 pubmed: 32129900
Chen Z, Ni W, Li JL et al (2021) The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI Insight 6:e139497. https://doi.org/10.1172/jci.insight.139497
doi: 10.1172/jci.insight.139497 pubmed: 33830080 pmcid: 8119194
Chen Z, Lin S, Li JL et al (2018) CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells. Oncogene 37:1885–1895. https://doi.org/10.1038/s41388-017-0104-0
doi: 10.1038/s41388-017-0104-0 pubmed: 29353885 pmcid: 5889358
Naakka E, Barros-Filho MC, Adnan-Awad S et al (2022) miR-22 and miR-205 Drive Tumor aggressiveness of Mucoepidermoid carcinomas of salivary glands. Front Oncol 11:786150. https://doi.org/10.3389/fonc.2021.786150
doi: 10.3389/fonc.2021.786150 pubmed: 35223452 pmcid: 8864291
Yoshimura T, Higashi S, Yamada S et al (2021) PCP4/PEP19 and HER2 are novel prognostic markers in Mucoepidermoid Carcinoma of the salivary gland. Cancers (Basel) 14:54. https://doi.org/10.3390/cancers14010054
doi: 10.3390/cancers14010054 pubmed: 35008217
Corrêa TS, Matos GDR, Segura M et al (2018) Second-line treatment of HER2-Positive salivary gland tumor: Ado-TrastuzumabEmtansine (T-DM1) after progression on Trastuzumab. Case Rep Oncol 11:252–257. https://doi.org/10.1159/000488669
doi: 10.1159/000488669 pubmed: 29867432 pmcid: 5981674
Nikolic N, Carkic J, IlicDimitrijevic I et al (2018) P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population. Oral Surg Oral Med Oral Pathol Oral Radiol 125:52–58. https://doi.org/10.1016/j.oooo.2017.09.013
doi: 10.1016/j.oooo.2017.09.013 pubmed: 29079368
Kang H, Tan M, Bishop JA et al (2017) Whole-exome sequencing of salivary gland Mucoepidermoid Carcinoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-0720 . 23:283 – 88
doi: 10.1158/1078-0432.CCR-16-0720 pubmed: 29246937 pmcid: 8487012
Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516. https://doi.org/10.1038/sj.bjc.6605788
doi: 10.1038/sj.bjc.6605788 pubmed: 20664595 pmcid: 2939786
Binmadi NO, Basile JR, Perez P et al (2018) miRNA expression profile of mucoepidermoid carcinoma. Oral Dis 24:537–543. https://doi.org/10.1111/odi.12800
doi: 10.1111/odi.12800 pubmed: 29095552
Flores BC, Lourenço SV, Damascena AS et al (2017) Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. Virchows Arch 470:291–299. https://doi.org/10.1007/s00428-016-2049-z
doi: 10.1007/s00428-016-2049-z pubmed: 27981346
Xu XF, Zhang TL, Jin S, Wang R, Xiao X, Zhang WD, Wang PY, Wang XJ (2013) Ardipusilloside I induces apoptosis by regulating Bcl-2 family proteins in human mucoepidermoid carcinoma Mc3 cells. BMC Complement Altern Med 13:322. https://doi.org/10.1186/1472-6882-13-322
doi: 10.1186/1472-6882-13-322 pubmed: 24256941 pmcid: 3874618
Choi SJ, Ahn CH, Hong KO et al (2021) Molecular mechanism underlying the apoptotic modulation by ethanol extract of Pseudolarixkaempferi in mucoepidermoid carcinoma of the salivary glands. Cancer Cell Int 21:427. https://doi.org/10.1186/s12935-021-02134-0
doi: 10.1186/s12935-021-02134-0 pubmed: 34391437 pmcid: 8364062
BouZerdan M, Kumar PA, Zaccarini D et al (2023) Molecular targets in salivary gland cancers: a comprehensive genomic analysis of 118 mucoepidermoid carcinoma tumors. Biomedicines 11:519. https://doi.org/10.3390/biomedicines11020519
doi: 10.3390/biomedicines11020519
da Silva GM, Saavedra V, Ianez RCF et al (2019) Apoptotic signaling in salivary mucoepidermoid carcinoma. Head Neck 41:2904–2913. https://doi.org/10.1002/hed.25763
doi: 10.1002/hed.25763 pubmed: 30968512
Bell D, Hanna EY (2012) Salivary gland cancers: biology and molecular targets for therapy. CurrOncol Rep. https://doi.org/10.1007/s11912-012-0220-5 . 14:166 – 74
doi: 10.1007/s11912-012-0220-5
Chintakuntlawar AV, Okuno SH, Price K (2016) Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck 1:11. https://doi.org/10.1186/s41199-016-0011-z
doi: 10.1186/s41199-016-0011-z pubmed: 31093341 pmcid: 6460835
Kurzrock R, Bowles DW, Kang H et al (2020) Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 31:412–421. https://doi.org/10.1016/j.annonc.2019.11.018
doi: 10.1016/j.annonc.2019.11.018 pubmed: 32067683
Andersson MK, Afshari MK, Andrén Y et al (2017) Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst 109. https://doi.org/10.1093/jnci/djx017
Su BH, Qu J, Song M, Huang XY, Hu XM, Xie J, Zhao Y, Ding LC, She L, Chen J, Lin LS, Lin X, Zheng DL, Lu YG (2014) NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma. Oncotarget 5(16):6885–6895. https://doi.org/10.18632/oncotarget.2321
doi: 10.18632/oncotarget.2321 pubmed: 25149541 pmcid: 4196170
Sajed DP, Faquin WC, Carey C, Severson EA, Afrogheh H, Johnson AA, Blacklow C, Chau SC, Lin NG, Krane DT, Jo JF, Garcia VY, Sholl JJ, Aster LM JC (2017) Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is Associated with worse outcome in Adenoid cystic carcinoma. Am J Surg Pathol 41(11):1473–1482. https://doi.org/10.1097/PAS.0000000000000945
doi: 10.1097/PAS.0000000000000945
Jee KJ, Persson M, Heikinheimo K, Passador-Santos F, Aro K, Knuutila S, Odell EW, Mäkitie A, Sundelin K, Stenman G, Leivo I (2013) Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol 26(2):213–222. https://doi.org/10.1038/modpathol.2012.154
doi: 10.1038/modpathol.2012.154
Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE (2019) Ablation of Cancer Stem cells by therapeutic inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res 25(5):1588–1600. https://doi.org/10.1158/1078-0432.CCR-17-2730
doi: 10.1158/1078-0432.CCR-17-2730 pubmed: 30498096
Firwana B, Atassi B, Hasan R, Hasan N, Sukari A (2012) Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature. Avicenna J Med 2(3):71–73. https://doi.org/10.4103/2231-0770.102282
doi: 10.4103/2231-0770.102282 pubmed: 23826550 pmcid: 3697425
Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E (2022) AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 13:678. https://doi.org/10.1038/s41419-022-05133-9
doi: 10.1038/s41419-022-05133-9 pubmed: 35931701 pmcid: 9355983
Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A (2023) Phase II clinical trial of Axitinib and Avelumab in patients with Recurrent/Metastatic adenoid cystic carcinoma. J Clin Oncol 41:2843–2851. https://doi.org/10.1200/JCO.22.02221
doi: 10.1200/JCO.22.02221 pubmed: 36898078
Miranda EL, Stathis A, Hess D, Racca F, Quon D, Rodon J, Gadea OSS, Garcia JMP, Nuciforo P, Vivancos A, Cortes J, Ferrarotto R, Schönborn-Kellenberger O, Vigolo M, Bobadilla M, Beni L, Lehal R, Bauer MP, Vogl FD, Garralda E (2021) Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. J Clin Oncol 39:3020–3020. https://doi.org/10.1200/JCO.2021.39.15_suppl.3020
doi: 10.1200/JCO.2021.39.15_suppl.3020
Mishra V, Singh A, Chen X, Korzinkin M, Wing C, Sarkisova V, Ozerova A, Glushchenko O, Thodima V, Ito K, Scherle P, Lingen M, Hasina R, Pearson A, Rosenberg A, Zhavoronkov A, Ruggeri B, Agrawal N, Izumchenko E (2023) PRT543, a methyl transferase inhibitor, has potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. Cancer Res 83:4897. https://doi.org/10.1158/1538-7445.AM2023-4897
doi: 10.1158/1538-7445.AM2023-4897
Chung V, Wang L, Fletcher MS, Massarelli E, Reckamp KL, Cristea MC, Prajapati N, Parikh N, Whiting A, Wang RL, Wu M J (2019) First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma. J Clin Oncol 37:TPS3146–TPS3146. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS3146
doi: 10.1200/JCO.2019.37.15_suppl.TPS3146
Hu X, Zhang J, Liu R, Gao S, Qing Y, Yi S, Yuan J, Chen H, Fan B, Zheng H, Wang J (2021) Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. J Clin Oncol 39:1024–1024. https://doi.org/10.1200/JCO.2021.39.15_suppl.1024
doi: 10.1200/JCO.2021.39.15_suppl.1024

Auteurs

Raisa Ferreira Costa (RF)

International Research Center, A.C.Camargo Cancer Center, Rua Taguá, 440 - Primeiro andar, São Paulo, 01508-010, Brazil.

Carolinne Alves de Oliveira (CA)

International Research Center, A.C.Camargo Cancer Center, Rua Taguá, 440 - Primeiro andar, São Paulo, 01508-010, Brazil.

Ágatha Nagli de Mello Gomes (ÁNM)

International Research Center, A.C.Camargo Cancer Center, Rua Taguá, 440 - Primeiro andar, São Paulo, 01508-010, Brazil.

Silvia Vanessa Lourenço (SV)

Department of General Pathology, Dental School, University of São Paulo, São Paulo, Brazil.

Cláudia Malheiros Coutinho-Camillo (CM)

International Research Center, A.C.Camargo Cancer Center, Rua Taguá, 440 - Primeiro andar, São Paulo, 01508-010, Brazil. ccamillo@accamargo.org.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs kystiques, mucineuses et séreuses › Carcinome mucoépidermoïde › Molecular Aspects of Mucoepidermoid Carcinoma...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular Aspects of Mucoepidermoid Carcinoma...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Carcinome adénoïde kystique › Molecular Aspects of Mucoepidermoid Carcinoma...
questionsmedicales.fr › Maladies du système stomatognathique › Maladies de la bouche › Maladies de la glande salivaire › Tumeurs des glandes salivaires › Molecular Aspects of Mucoepidermoid Carcinoma...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Molecular Aspects of Mucoepidermoid Carcinoma...